Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社, Fujisawa Yakuhin Kōgyō Kabushiki-gaisha). On February 5, 2020, the company announced management changes effective from April 1, 2020. Astellas is a member of the Mitsubishi UFJ Financial Group (MUFJ) keiretsu. In June 2016, the Association of the British Pharmaceutical Industry (ABPI) gave Astellas a year-long suspension, after complaints it had "purposely misled the PMCPA." In particular, Astellas had not fully disclosed the nature of a meeting which had purported to be a "genuine advisory board". More information...
According to PR-model, astellas.com is ranked 98,351st in multilingual Wikipedia, in particular this website is ranked 12,595th in Japanese Wikipedia.
The website is placed before sadokisen.co.jp and after academiajoaocapela.com in the BestRef global ranking of the most important sources of Wikipedia.
